CagriSema (10mg Dual Incretin Blend)
Analytical Standards & Laboratory Handling
Verified laboratory protocols, reconstitution parameters, and handling guidelines.
Pharmacological Profile & Mechanism of Action
What it is: CagriSema is an advanced dual-hormone combination peptide pairing Cagrilintide (a long-acting amylin analogue) and Semaglutide (a validated GLP-1 receptor agonist) in a precise 1:1 stoichiometric ratio (5mg / 5mg).
How it works: By concurrently engaging the area postrema and ventral tegmental area via calcitonin/RAMP amylin receptor complexes while stimulating hypothalamic GLP-1 receptors, CagriSema produces profound synergistic suppression of appetite, deceleration of gastric emptying, and restoration of glycemic setpoints exceeding either agent alone.
Why researchers study it: Investigated in Phase 3 trials (REDEFINE program) for unmatched weight reduction (exceeding 25% in clinical cohorts) and significant improvements in cardiovascular and metabolic biomarkers.
Compound & Molecular Specifications
Certificate of Analysis StandardsAll-in-One Pre-Mixed Peptide Formulation
This product is a Blend (1 physical vial) where active peptide compounds are co-lyophilized into a single cake for simplified reconstitution. If your research requires staggered administration windows (e.g. Fasted AM vs Pre-Bed PM) or custom stoichiometric titrations, you can stack separate vials in our Stacking Studio.
